Sep 28, 2023

Featuring an interview with Dr Paul G Richardson, including the following topics:

• Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
• Similarities and differences between iberdomide, mezigdomide and standard immunomodulatory drugs (7:14)
• Compassionate use of melflufen and belantamab mafodotin (12:08)
• Current management strategies for newly diagnosed MM (16:30)
• DETERMINATION: Evaluation of trial findings on racial and ethnic disparities and differential outcomes (23:02)
• Tailoring of up-front daratumumab-based therapies; management of extramedullary disease (33:17)

CME information and select publications